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Abstract
Metastatic dissemination with subsequent clinical outgrowth leads to the greatest part of morbidity
and mortality from most solid tumors. Even more daunting is that many of these metastatic
deposits silently lie undetected, recurring years to decades after primary tumor extirpation by
surgery or radiation (termed metastatic dormancy). As primary tumors are frequently curable, a
critical focus now turns to preventing the lethal emergence from metastatic dormancy. Current
carcinoma treatments include adjuvant therapy intended to kill the cryptic metastatic tumor cells.
Because such standard therapies mainly kill cycling cells, this approach carries an implicit
assumption that metastatic cells are in the mitogenic cycle. Thus, the pivotal question arises as to
whether clinically occult micrometastases survive in a state of balanced proliferation and death, or
whether these cells undergo at least long periods of quiescence marked by cell cycle arrest. The
treatment implications are thus obvious – if the carcinoma cells are cycling then therapies should
target cycling cells, whereas if cells are quiescent then therapies should either maintain dormancy
or be toxic to dormant cells. Because this distinction is paramount to rational therapeutic
development and administration, we investigated whether quiescence or balanced proliferation is
the most likely etiology underlying metastatic dormancy. We recently published a computer
simulation study that determined that balanced proliferation is not the likely driving force and that
quiescence most likely participates in metastatic dormancy. As such, a greater emphasis on
developing diagnostics and therapeutics for quiescent carcinomas is needed.
Introduction to metastatic dormancy
Advances in cancer treatment, underpinned by a growing understanding of tumor biology,
have rendered the majority of localized solid tumors either curable or controllable. Surgical
and radiological interventions have improved to the point that the initial primary tumor can
be extirpated. However, if the primary tumor gives rise to clinically-detectable metastatic
lesions, current therapies usually only delay mortality and are not curative. Most daunting to
patients faced with treatment decisions for disease that is “non-metastatic” at the time of
primary tumor diagnosis is that metastatic dissemination may have already occurred despite
the primary lesion “being cured” by removal. Many of these metastatic tumors will appear
years or more than a decade later, thus termed metastatic dormancy. Although this
phenomenon afflicts nearly half of carcinoma patients that develop metastases (1), the cell
biology of this remains unknown. Proposed dormancy mechanisms range from cell cycle
arrest, immune function dysregulation, angiogenic insufficiency, stress related kinase and
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urokinase receptor imbalance, to tumor/stroma biomechanics (2–5). Fundamentally these
vary between the orthogonally opposed dormancy mechanisms of cellular quiescence or
balanced proliferation (mitogenesis equally offset by apoptosis). Spotlighting this difference
is critical because therapeutics in the clinic and under development largely target cycling,
not quiescent carcinoma cells.
This metastatic dormancy, while present in most all cancers, is particularly insidious for
carcinomas of the mammary gland. For breast cancer, up to one third of small (1 cm or less),
non-invasive (or micro-invasive) carcinomas with no evidence of metastasis will become
evident at distant sites within the decade following diagnosis of the primary tumor (1). For
this reason, adjuvant chemotherapy, aimed at killing cycling tumor cells, is an option after
successful lumpectomy. This adjuvant therapy has been met with limited success for most
incarnations of breast carcinoma, as adjuvants reduce metastatic recurrences by only a third
(on average) at ten years (6). The reasons for this therapeutic failure in breast and other
epithelial carcinomas can be summarized by two possibilities – the tumors are inherently
resistant to the agents used, or the disseminated tumor cells are not cycling (1, 7).
Prognostic assays for metastatic dormancy
This is the key unknown in metastatic dormancy, whether the clinically silent
micrometastases are in a state of balanced proliferation and death or if they exist as
mitogenically quiescent (8). The phenotype and genomic fingerprints of the primary tumor
often suggests quiescence. Two distinct molecular algorithms are used clinically to predict
breast cancer recurrence (http://www.agendia.com/pages/mammaprint/21.php and
www.oncotypedx.com), and while they do not utilize the same genes, there is a
preponderance of mitosis-related genes that correlate with recurrence consistent with most
proposed signatures (9). Further, triple negative (ER-, PR-, HER-2-) mammary tumors are
generally aggressive, highly proliferative, highly recurrent tumors that are treated with
adjuvant chemotherapy, but can be considered eliminated (or senescent) if there is no
metastatic recurrence after about three years. These clinical correlates suggest that the latent
tumor cells at the metastatic sites may also have low rates of cycling.
The drawback to these and other current prognostic assays is that the cells examined are
from the primary tumor site, where the preponderance of cells likely lacks the necessary
traits for successfully seeding, surviving or expanding in the metastatic microenvironment.
While each step in the metastatic cascade (separation from the primary tumor, intravasation
into a conduit, survival in that conduit, extravasation, and finally successful seeding of an
ectopic organ) is inefficient, ectopic survival appears to be the most rate-limiting step.
Careful enumeration of these stages in animal models shows that it is the establishment of a
small number of surviving cells in the metastatic target organ that is the least efficient (10,
11). Interestingly, the few cells found weeks after seeding in these animal models were not
highly proliferative (12). Still, these are among the few studies that have examined the early
stages of tumor metastasis. As true human metastatic dormancy (as noted after years to
decades) cannot be approached in rodent models (though initial steps of attaining dormancy
may be noted in these short-lived animals), it is critical to consider the quiescent behavior of
these tumor cells in the human context to direct therapeutic and diagnostic approaches.
Computer simulation revealing quiescence as integral to metastatic
dormancy
We recently implemented an in silico model to determine the survival probability range that
carcinoma micrometastases in a state of balanced proliferation would yield the dormant
phenotype (13). Although many other computer simulations have been developed to model
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metastasis (14–16), none of these approaches have explored the survival probability
requirements of the metastatic niche necessary to confer a dormant phenotype. We
employed a Markov chain Monte Carlo approach that sampled from a probability
distribution to assign either a divide or die condition to each cell in each simulated
metastasis. Survival probabilities were assigned ranging from 30 to 70 percent with an
additional stochastic 10 percentage point probability adjustment at each sampling. So for
example, at 40 percent survival probability metastatic cells would survive between 30 and
50 percent of the time, thus providing an additional alignment to the fluxing survival
conditions of the metastatic niche. We assumed that any given patient could have 1000
independent metastatic deposits at the time of primary tumor removal. By defining active
cycling as a 3 – 5 day mitogenic window, 1218 cycles equated to a 5 – 10 year metastatic
dormancy before the metastases reached the clinically detectable level of one million cells or
more. By traversing the survival probability from 30 to 70 percent during each cycle, we
identified the boundary conditions at which any micrometastases might remain in a dormant
phenotype over the entire time period (without any metastases in that ‘peron’ clinically
emerging). Surprisingly, this survival probability window was narrow, being only about one
percentage point wide, from a probability of 49.7 to 50.8 percent (Figure 1). Even more
interesting, the width of this survival probability was independent of the assumed starting
size of the micrometastases (1 – 8 starting cells). While it is generally accepted that solitary,
extravasated cells initiate metastases and may become quiescent, we also simulated a burst
of proliferation prior to establishment of a micrometastasis by modeling metastases starting
at 2000 cells. While these larger starting metastases maintained the dormant phenotype, the
survival probability window remained the same one percentage point. At survival
percentages even just slightly lower than 49 percent, all micrometastases rapidly died out,
and by 55 percent there was rapid outgrowth of clinical metastases (<100 cycles to exceed
one million cells) that were more indicative of progressive metastatic disease. This
suggested (at least theoretically) that it would be unlikely during extended human clinical
dormancy that the tumor cells would exclusively exist in a state of continuous cycling with
matched cell death (balanced proliferation).
This analysis assumed a homogenous population behavior (divide or die at each cycle) even
though the survival probabilities were stochastic at any given cycle for each metastatic cell.
The remarkably small probability window for dormancy in a balanced proliferation/death
model holds from at least 1 to 2000 starting cells. Obviously, if we significantly extended
the cycle time beyond 72 hours, or introduced intermissions into cycling, the probability
window would broaden slightly; however this would merely reinforce the finding that
balanced proliferation and death is not likely the sole mechanism for metastatic dormancy. It
should be noted that the model does not account for the processes leading to micrometastatic
establishment (escape, transit, extravasation, etc), nor does it address the starting the point
for quiescence, nor determine that the quiescent state is uninterrupted; these issues are to be
addressed in further modeling studies. Although this model has shortcomings as noted here
and in the original article (including that simulated metastases do not spawn secondary
metastases), that such a narrow survival probability was defined is highly suggestive of a
critical role for quiescence. Although this model was not designed to statistically reject a
null hypothesis that balanced proliferation plays a dominant role in metastatic dormancy,
that only a single, narrow, and contiguous survival probability led to metastatic dormancy
does not reasonably align with our biological understanding of the metastable nature of the
metastatic niche (unless the cells undergo periods of quiescence). A conceptually different
invocation of additional events for metastatic emergence, such as angiogenesis or failure of
suppressive events to allow for further metastatic growth (4, 17, 18), only invoke the trigger
for quiescence but do not alter the idea that for extended tumor dormancy, the
micrometastatic cells likely undergo mitogenic quiescence for at least extended periods.
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In vivo investigations into metastatic dormancy
The question arises as to whether dormant metastases that undergo cellular quiescence align
with clinical and experimental findings. Studies that directly examine dormant
micrometastases are few and hampered by the lack of clinical samples or limitations of
experimental systems (4, 7). From the experimental side, there have been a number of
interventions to regulate cellular quiescence and determine the effects on tumor growth and
persistence in host animals (19–21). The outcomes and correlation of low proliferative rate
with metastatic dormancy are consistent with a cellular quiescence hypothesis rather than
balanced proliferation. Further, the conversion of micrometastatic cells from a mesenchymal
phenotype to a more epithelial one (22–24), also is supportive as these epithelioid tumor
cells tend to have a reduced mitogenic rate. Additional support come from recent in vivo
work that demonstrated that TGF-β receptor blockade prevents dormancy by
microenvironmental BMP (25). In fact, the authors identified a genetic signature that is
predictive of breast cancer organotropism to lung versus other common metastatic sites such
as liver and brain.
Another open question concerns that state at which disseminated tumor cells enter
dormancy. While the angiogenic switch model implies a later event after the
micrometastasis goes through numerous cell cycles, others suggest a very early event
possibly at the single cell level (25). Work by the Welch group has investigated single cell
metastatic dormancy in vivo and provides insights into mechanisms such as breast cancer
metastasis suppressor 1 (BRMS1) and kisspeptin (KISS1) (26–28). These provide
mechanistic bases to the earlier work which counted solitary cells surviving in ectopic sites
(10). However, in these experiments it is not clear whether these persisting disseminated
cancer cells give rise to the later outgrowth. Regardless, the model tested demonstrated the
same narrow probability range whether the initially established micrometastatic nodule
contained 1 or up to 2000 cells; only the number of dormant metastases varied based on cell
number (13).
The human observations are also consistent with the cellular quiescence model.
Disseminated tumor cells isolated from bone marrow even after removal of the primary
lesion have been found to have low proliferation rates by mitogenic markers, and low to
undetectable levels of activated AKT as a key signaling nexus in tumor cell mitogenesis (29,
30). Still these singular cells in bone marrow are not the micrometastatic foci one might
consider as potentially emergent. Unfortunately, such early small lesions are not often
observed and studied in human patients. However, where data have been gathered, it has
been found that such tumor foci are often highly epithelial, and morphologically quiescent
rather than the mesenchymal-like phenotype displayed by their paired primary lesions (31–
33).
Work on defining metastatic dormancy signatures provide fodder for both cellular
quiescence and externally constrained growth (balanced proliferation). For instance, an
angiogenic signature predicted tumor outgrowth in a mouse model (34), while G0-like
quiescence was noted in a squamous carcinoma xenograft model (35). Combining such
mouse model and in vitro networks derived from arrested cells, a 49 gene signature emerged
that correlated with clinical dormancy in a retrospective analysis of human mammary
carcinomas (36). These genetic signatures might be predictive of metastatic dormancy in the
human condition and serve as a foundation to explore mechanisms to either maintain
metastatic dormancy or induce emergence.
Another data set from which we may draw conclusions relates to the seeming
chemoresistance of micrometastases. This can be due to cellular quiescence, inherent
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chemoresistance, resistance due to the microenvironment (signals or privileged site), or a
combination of the preceding; or even simply an artifact of observation. Artifactual
observations can arise from the inherent nature of logarithmic doubling in which an
impressive 99% reduction in cell number would translate to only a two-week delay during
the emergent phase of tumor cell outgrowth. However, studies have shown that metastatic
cells are relatively more chemoresistant than paired primaries when challenged with a range
of therapies due to the combination of microenvironmental signals and inherent cell
properties (37–40). It also must be noted that noncycling or quiescent cells are generally
more resistant to killing by a variety of insults including chemotherapies, and while this is
not likely the sole reason for the resistance of metastases, mitogenic quiescence would be
contributory. Still, the clinical experience suggests that in most carcinomas, chemotherapy
rarely cures clinically-evident metastases but rather reduces the tumor burden and prolongs
life. However, the integration of the experimental and observational findings to-date suggest
that the cellular quiescence model is consistent with clinical dormancy, but these
suggestions fall short of being convincing.
What is needed is a comprehensive approach to metastatic dormancy in which the cellular
processes can be evaluated longitudinally, and in real time. True appreciation of the full
span of metastatic dormancy requires human patients due to the time-length of the
phenomenon and the spontaneous nature of such metastases that confound the existing
experimental models (8). However, attempts have been made to use the human patient as an
experimental system by examining disseminated tumor cells found in bone marrow and
circulation (4). Given the relative abundance of such cells coupled with the rarity of actual
emergent metastases, it is quite possible that the vast majority of these cells are pre-
senescent or pre-apoptotic and thus not representative of dormant micrometastases. Rather,
one would desire intravital imaging of human micrometastases, a capability for which
advances in PET and other imaging modalities are striving. However, this is currently not
available, and one could envision that the putative cellular quiescence would defeat efficient
labeling and detection of such micrometastases.
Microphysiological 3D bioreactors to study metastatic dormancy
We are taking a different approach to examining the early stages of metastatic seeding and
dormancy in an all human microphysiological bioreactor (23) (Figure 2). This ex vivo
system allows for metastatic seeding and entry into dormancy to be examined at a cellular
level for up to several weeks. This exceeds the hours-long window possible in animal
models (11, 41, 42) and is beneficial over the random terminal endpoints of long-term
metastasis studies in animals and humans. Even with the limitations of having incomplete
vascular and immune systems and lacking neural innervation, this system provides for the
complex multicellular and matrix interactions within the metastatic niche comprising human
cells. In this manner, one can determine whether tumor cells can enter cellular quiescence.
Initial work suggests that cellular quiescence or entry into dormancy is finely regulated, and
dependent on numerous factors including tissue rheology, fluid/blood flow, oxygen tension
and nutrient and hormone levels. For instance, a stiff supporting matrix, possibly
representative of fibrosis, drives carcinoma cells towards progressive metastatic growth; this
may underlie the puzzling phenomenon of cells that attain at least short term dormancy in
vivo growing in 3D cultures in vitro. While there are other systems with which to probe
dormancy, we are providing this on a template for discussion.
Conclusions
The real importance of determining whether the balanced proliferation or cellular quiescence
model holds sway is the therapeutic implications of such. Proliferating cells allow for a
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distinct set of agents and strategies; mainly the routine chemotherapies could be valuable as
they target mainly cycling cells. On the other hand, if the metastatic cells are quiescent (in a
G0 or G1 state), these agents would likely not be efficacious. Therefore, strategies should
then be aimed not just at extirpating the cells but also could be designed to keep the cells in
a state of indolent dormancy. In fact, generalized toxic therapies might actually be
detrimental as the collateral damage to the parenchymal or stromal cells may lead to an
inflammatory state; there are suggestions that such an inflammatory milieu may ‘awaken’
the surrounding dormant micrometastases. In such a situation, adjuvant chemotherapy may
not only be contra-indicated due to toxicity, but also due to shortening overall patient
survival. Thus, the critical question as to whether the micrometastatic cells are in a state of
quiescence or balanced proliferation is the key to dealing with tumor dormancy, and should
be at the forefront of new approaches to tumor management.
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Figure 1.
Probability of dormancy from in silico simulation. Dormancy is defined by a metastasis
achieving 1,218 cycles while having a cell number greater than zero and below 1 million.
The simulated balanced proliferation yields a dormant phenotype for patients harboring
1000 cryptic micrometases only between 49.7 – 50.8 percent survival probability regardless
of starting cell number in the micrometasasis. Panel A shows the absolute number of
dormant metastases at the end of the 1,218 cycles for a starting number of 2 cells per
micrometastasis. Panel B depicts the metastatic fate for each of the survival probabilities
demonstrating that same dormancy window (in red). The green area demonstrates that the
majority of metastases die out even at survival probabilities approaching 60 percent.
Metastases that become clinically evident (exceed 1 million cells) are shown in purple. From
(13).
Wells et al. Page 9
Cancer Res. Author manuscript; available in PMC 2014 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Schematic of an approach to study metastatic dormancy. The development of
microphysiological systems such as organotypic bioreactors allows for the examination of
cellular events in metastatic seeding and entry into dormancy or continuous outgrowth for a
multiweek period (43). Shown is a cartoon depicting the fate of the micrometastasis
following from the host tissue being in a more physiological state (upper pathway) versus a
stressed, inflammaned or fibrotic organ (lower pathway). The stressed pathway prohibits
micrometastases from entering dormancy while supporting emergence into frank metastases.
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